|
Vitamin K epoxide reductase complex subunit 1 (VKORC1): A pharmacogenomic predictor of response and survival in patients (pts) on triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-Cet) for initially unresectable liver metastases from colorectal cancer (uLM-CRC) (EU trial OPTILIV). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Baxalta; Celgene; Lilly; Merck; Roche; Sanofi; Sirtex Medical |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bayer; Celgene; Ipsen; Lilly; Merck Serono; Novartis; Roche; SERVIER |
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Celgene; Merck Serono; Roche; SERVIER |
Research Funding - Merck Serono (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bayer; Celgene; Ipsen; Merck Serono; Roche |
Other Relationship - Sandoz (I) |
|
|
Honoraria - Amgen; Astellas Oncology; Merck; Sanofi |
Consulting or Advisory Role - Amgen; Merck |
Travel, Accommodations, Expenses - Amgen; Astellas Oncology; Merck; Sanofi |
|
|
No Relationships to Disclose |